

**PCR-/NAT *Clostridium difficile***  
**(RV 545) November 2021**



**Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.**

*Sample composition and expected results.*

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
2125451	∅	62	<i>Escherichia coli</i> K12
2125452	+++	61 / 71,72	<i>Clostridium difficile</i> (~ 5x10 <sup>5</sup> CFU/mL)
2125453	∅	62	<i>Escherichia coli</i> K12
2125454	++	61 / 71,72	<i>Clostridium difficile</i> (~ 5x10 <sup>4</sup> CFU/mL)

**Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.**

*Absolute numbers of reported individual results.*

<i>n = 162</i>	<i>Probennummer (Sample no.)</i>				<i>Inhibition</i>				
	2125451	2125452	2125453	2125454	2125451	2125452	2125453	2125454	
<b>Befund</b> <i>Result</i>									
<b>Positiv</b>	2	159	2	160	n.d.	2	2	2	2
<b>Negativ</b>	160	1	160	2	nein <i>no</i>	160	158	160	160
<b>Fraglich</b> <i>Questionable</i>	0	2	0	0	ja <i>yes</i>	0	2	0	0

**Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.**

*Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.*

<b>NAT-Methode</b> [Code] (total number *)	<b>NAT richtig positiv</b> <i>True positive results</i>				<b>NAT richtig negativ</b> <i>True negative results</i>			
	2125452		2125454		2125451		2125453	
	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%
Altona RealStar <i>C. difficile</i> (n = 5)	5	100	5	100	5	100	5	100
Amplex eazyplex <i>C. difficile</i> (n = 2)	2	100	2	100	2	100	2	100
AmpliGnost <i>C. difficile</i> Tox. A + B (n = 2)	2	100	2	100	2	100	2	100
BD MAX <i>C. difficile</i> (n = 21)	21	100	21	100	21	100	21	100
HAIN GenoType CDiff (n = 1)	1	100	1	100	1	100	1	100
Cepheid Xpert <i>C. difficile</i> (n = 60)	58*	97	58	97	59	98	59	98
Meridian Alethia <i>C. difficile</i> (n = 7)	7	100	7	100	7	100	7	100

<b>Quidel Solana C. difficile (n = 5)</b>	<b>5</b>	<b>100</b>	<b>5</b>	<b>100</b>	<b>5</b>	<b>100</b>	<b>4</b>	<b>80</b>
<b>Seegene Allplex GI Bacteria (n = 6)</b>	<b>6</b>	<b>100</b>	<b>6</b>	<b>100</b>	<b>6</b>	<b>100</b>	<b>6</b>	<b>100</b>
<b>Seegene Allplex GI-EB Screening (n = 5)</b>	<b>5</b>	<b>100</b>	<b>5</b>	<b>100</b>	<b>5</b>	<b>100</b>	<b>5</b>	<b>100</b>
<b>LightMix Cdiff Toxin Gene tcdA/tcdB (n= 2)</b>	<b>2</b>	<b>100</b>	<b>2</b>	<b>100</b>	<b>2</b>	<b>100</b>	<b>2</b>	<b>100</b>
<b>RIDAGENE C.diff. (n = 22)</b>	<b>22</b>	<b>100</b>	<b>22</b>	<b>100</b>	<b>22</b>	<b>100</b>	<b>22</b>	<b>100</b>
<b>RIDAGENE Hospital stool panel (n = 5)</b>	<b>5</b>	<b>100</b>	<b>5</b>	<b>100</b>	<b>5</b>	<b>100</b>	<b>5</b>	<b>100</b>
<b>In house PCR assay (n = 12)</b>	<b>12</b>	<b>100</b>	<b>12</b>	<b>100</b>	<b>11</b>	<b>92</b>	<b>12</b>	<b>100</b>
<b>Other commercial tests (n = 7)</b>	<b>6*</b>	<b>86</b>	<b>7</b>	<b>100</b>	<b>7</b>	<b>100</b>	<b>7</b>	<b>100</b>

\* Inhibition

Unter "**Andere kommerzielle Testsysteme**" wurden diesmal folgende Testsysteme aufgeführt: Roche COBAS Liat Cdiff (2x), Bio-Speedy C. difficile Real-Time PCR (1x), Aries Luminex C. difficile (1x), Abacus Diagnostica GenomEra C. difficile (1x) und DiaSorin Simplexa C. difficile Direct Kit (1x).